Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill prevent dangerous clots after joint surgery?

NCT ID NCT05449327

Disease control Sponsor: Chiayi Christian Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether the blood thinner Xarelto (rivaroxaban) can prevent dangerous blood clots in the legs or lungs after hip or knee replacement surgery. 150 patients were randomly assigned to receive either Xarelto or no blood thinner after surgery. The researchers tracked how many developed clots or had complications like bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rivaroxaban (Xarelto)
What this could lead to
If successful, this could confirm that Xarelto is a safe and effective option to prevent blood clots after joint replacement surgery in Taiwanese patients.
What could go wrong
This is a small, completed study with only 150 participants, so results may not apply to everyone. There is also a risk of bleeding or other complications from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

150 people

The number who actually took part.

Started

Feb 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergo total knee replacement or total hip replacement Exclusion Criteria: * Recent antithrombotics use * A history of a coagulopathy * Recent thromboembolic disease * Preoperative deep vein thrombosis screening presents positive * Age below 20

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthroplasty Venous thromboembolism

Contacts and locations

Locations

  • Ditmanson Medical Foundation Chiayi Christian Hospital

    Chiayi City, Taiwan, 60002, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.